Trial · NCT02558231
Results by group30
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 30
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline to Week 26 in Pulmonary Vascular Resistance (PVR) | Triple Oral Therapy (Macitentan, Tadalafil, and Selexipag) | 0.46 | 95% Confidence Interval 0.422 to 0.503 | ratio | |
| Change From Baseline to Week 26 in Pulmonary Vascular Resistance (PVR) | Double Oral Therapy (Macitentan, Tadalafil, and Placebo) | 0.48 | 95% Confidence Interval 0.441 to 0.526 | ratio | |
| Change From Baseline to Week 26 in 6-minute Walk Distance (6MWD) | Triple Oral Therapy (Macitentan, Tadalafil, and Selexipag) | 54.96 | 95% Confidence Interval 40.419 to 69.501 | meter | |
| Change From Baseline to Week 26 in 6-minute Walk Distance (6MWD) | Double Oral Therapy (Macitentan, Tadalafil, and Placebo) | 56.39 | 95% Confidence Interval 41.447 to 71.327 | meter | |
| Change From Baseline to Week 26 in N-terminal Pro B-type Natriuretic Peptide (NT-proBNP) Levels | Triple Oral Therapy (Macitentan, Tadalafil, and Selexipag) | 0.26 | 95% Confidence Interval 0.206 to 0.328 | ratio | |
| Change From Baseline to Week 26 in N-terminal Pro B-type Natriuretic Peptide (NT-proBNP) Levels | Double Oral Therapy (Macitentan, Tadalafil, and Placebo) | 0.25 | 95% Confidence Interval 0.200 to 0.320 | ratio | |
| Percentage of Participants With Absence of Worsening From Baseline to Week 26 in World Health Organization (WHO) Functional Class (FC) | Triple Oral Therapy (Macitentan, Tadalafil, and Selexipag) | 99.2 | percentage of participants | ||
| Percentage of Participants With Absence of Worsening From Baseline to Week 26 in World Health Organization (WHO) Functional Class (FC) | Double Oral Therapy (Macitentan, Tadalafil, and Placebo) | 97.5 | percentage of participants | ||
| Change From Baseline to Week 26 in Mean Pulmonary Arterial Pressure (mPAP) | Triple Oral Therapy (Macitentan, Tadalafil, and Selexipag) | -12.92 | 95% Confidence Interval -14.609 to -11.235 | millimeters of mercury (mmHg) | |
| Change From Baseline to Week 26 in Mean Pulmonary Arterial Pressure (mPAP) | Double Oral Therapy (Macitentan, Tadalafil, and Placebo) | -12.20 | 95% Confidence Interval -13.881 to -10.515 | millimeters of mercury (mmHg) | |
| Change From Baseline to Week 26 in Mean Right Atrial Pressure (mRAP) | Triple Oral Therapy (Macitentan, Tadalafil, and Selexipag) | -1.78 | 95% Confidence Interval -2.512 to -1.045 | mmHg | |
| Change From Baseline to Week 26 in Mean Right Atrial Pressure (mRAP) | Double Oral Therapy (Macitentan, Tadalafil, and Placebo) | -1.69 | 95% Confidence Interval -2.429 to -0.955 | mmHg | |
| Change From Baseline to Week 26 in Total Pulmonary Resistance | Triple Oral Therapy (Macitentan, Tadalafil, and Selexipag) | -511.88 | 95% Confidence Interval -569.36 to -454.40 | dynes*second per centimeter^5 | |
| Change From Baseline to Week 26 in Total Pulmonary Resistance | Double Oral Therapy (Macitentan, Tadalafil, and Placebo) | -514.28 | 95% Confidence Interval -571.45 to -457.11 | dynes*second per centimeter^5 | |
| Change From Baseline to Week 26 in Cardiac Index | Triple Oral Therapy (Macitentan, Tadalafil, and Selexipag) | 0.97 | 95% Confidence Interval 0.814 to 1.130 | liters per minute per meter square | |
| Change From Baseline to Week 26 in Cardiac Index | Double Oral Therapy (Macitentan, Tadalafil, and Placebo) | 0.84 | 95% Confidence Interval 0.684 to 0.997 | liters per minute per meter square | |
| Change From Baseline to Week 26 in Venous Oxygen Saturation (%) | Triple Oral Therapy (Macitentan, Tadalafil, and Selexipag) | 5.59 | 95% Confidence Interval 4.370 to 6.801 | percentage of oxygen saturation | |
| Change From Baseline to Week 26 in Venous Oxygen Saturation (%) | Double Oral Therapy (Macitentan, Tadalafil, and Placebo) | 6.79 | 95% Confidence Interval 5.561 to 8.020 | percentage of oxygen saturation | |
| Number of Participants With Disease Progression Event | Triple Oral Therapy (Macitentan, Tadalafil, and Selexipag) | Week 26 | 8 | Participants | |
| Number of Participants With Disease Progression Event | Double Oral Therapy (Macitentan, Tadalafil, and Placebo) | Week 26 | 13 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02558231/results